The 50-day moving average for INMD moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 56 cases where INMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INMD as a result. In 77 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for INMD turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 34 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for INMD entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INMD's RSI Oscillator exited the oversold zone, 29 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
Following a +3.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where INMD advanced for three days, in 164 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
INMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.219) is normal, around the industry mean (4.137). P/E Ratio (10.750) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (0.834) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.452) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 63 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. INMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
RVTY saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 62 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 70%.
The 10-day RSI Indicator for RVTY moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 21 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 68%.
The Moving Average Convergence Divergence Histogram (MACD) for RVTY turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 29 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RVTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
RVTY broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where RVTY advanced for three days, in 200 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 112 of 186 cases where RVTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. RVTY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.394) is normal, around the industry mean (65.710). P/E Ratio (74.572) is within average values for comparable stocks, (4.185). Projected Growth (PEG Ratio) (0.734) is also within normal values, averaging (3.473). Dividend Yield (0.002) settles around the average of (0.002) among similar stocks. P/S Ratio (5.656) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 86 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVTY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
INMD | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 63 | 86 | |
PRICE GROWTH RATING 1..100 | 69 | 36 | |
P/E GROWTH RATING 1..100 | 8 | 9 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INMD's Valuation (62) in the null industry is in the same range as RVTY (79) in the Medical Specialties industry. This means that INMD’s stock grew similarly to RVTY’s over the last 12 months.
INMD's Profit vs Risk Rating (100) in the null industry is in the same range as RVTY (100) in the Medical Specialties industry. This means that INMD’s stock grew similarly to RVTY’s over the last 12 months.
INMD's SMR Rating (63) in the null industry is in the same range as RVTY (86) in the Medical Specialties industry. This means that INMD’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (36) in the Medical Specialties industry is somewhat better than the same rating for INMD (69) in the null industry. This means that RVTY’s stock grew somewhat faster than INMD’s over the last 12 months.
INMD's P/E Growth Rating (8) in the null industry is in the same range as RVTY (9) in the Medical Specialties industry. This means that INMD’s stock grew similarly to RVTY’s over the last 12 months.
| INMD | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 68% |
| Stochastic ODDS (%) | 2 days ago 68% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 67% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 66% |
| Advances ODDS (%) | 4 days ago 64% | 10 days ago 67% |
| Declines ODDS (%) | 2 days ago 73% | 3 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 64% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 60% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INMD’s FA Score shows that 1 FA rating(s) are green while RVTY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INMD’s TA Score shows that 3 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s).
INMD (@Medical/Nursing Services) experienced а +0.83% price change this week, while RVTY (@Medical Specialties) price change was -1.20% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -3.27%. For the same industry, the average monthly price growth was -8.05%, and the average quarterly price growth was -7.48%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -6.42%. For the same industry, the average monthly price growth was -7.90%, and the average quarterly price growth was +34.49%.
INMD is expected to report earnings on Nov 11, 2026.
RVTY is expected to report earnings on Feb 04, 2027.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-6.42% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, INMD has been loosely correlated with UTMD. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if INMD jumps, then UTMD could also see price increases.
| Ticker / NAME | Correlation To INMD | 1D Price Change % | ||
|---|---|---|---|---|
| INMD | 100% | -0.52% | ||
| UTMD - INMD | 47% Loosely correlated | +1.68% | ||
| RVTY - INMD | 45% Loosely correlated | +2.84% | ||
| CRL - INMD | 45% Loosely correlated | +7.83% | ||
| MTD - INMD | 45% Loosely correlated | +2.57% | ||
| AZTA - INMD | 45% Loosely correlated | +4.76% | ||
More | ||||
A.I.dvisor indicates that over the last year, RVTY has been closely correlated with TMO. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if RVTY jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To RVTY | 1D Price Change % | ||
|---|---|---|---|---|
| RVTY | 100% | +2.84% | ||
| TMO - RVTY | 70% Closely correlated | +2.63% | ||
| A - RVTY | 63% Loosely correlated | +1.73% | ||
| AZTA - RVTY | 63% Loosely correlated | +4.76% | ||
| BIO - RVTY | 60% Loosely correlated | +3.41% | ||
| WAT - RVTY | 60% Loosely correlated | +1.00% | ||
More | ||||